LONDON (Alliance News) - Cancer immuotherapies developer Scancell Holdings PLC on Friday said it has suspended dosing with its current clinical trial supplies for its SCIB1 treatment with immediate effect.
Scancell said ongoing quality control analysis has found the stored drug product no longer meets the original specifications for the trial and has concluded it is no longer suitable for further use. No side effects from the use of the drug have emerged, Scancell said.
The suspension will effect eight patients in the trial, which is investigating the use of SCIB1 as a monotherapy for the treatment of melanoma.
Scancell said it intends to make a fresh batch of SCIB1 and has recently signed an agreement with a manufacturer.
"Patient safety has always been our primary responsibility. Although we have seen no new adverse events it is unfortunate, but nevertheless appropriate, that we suspend dosing of SCIB1 at this time while we work as quickly as possible to secure new supplies of this promising potential treatment for melanoma," said Scancell Chief Executive Richard Goodfellow.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)